迪瑞医疗董秘回复：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任

证券之星03-28

证券之星消息，迪瑞医疗(300396)03月28日在投资者关系平台上答复投资者关心的问题。投资者：目前的控股股东，2025年就要到期了，未来是要转让股权吗？迪瑞医疗董秘：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任。控股股东一直坚定于助力公司成为体外诊断领域的引领者，指导公司战略布局，通过管理赋能和业务赋能不断向公司输送资源，以推动公司的高质量发展，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422165007?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-28 18:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2422165007","market":"hk","top_or_hot":-1,"title":"迪瑞医疗董秘回复：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任","media":"证券之星","content":"<div>\n<p>证券之星消息，迪瑞医疗(300396)03月28日在投资者关系平台上答复投资者关心的问题。投资者：目前的控股股东，2025年就要到期了，未来是要转让股权吗？迪瑞医疗董秘：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任。控股股东一直坚定于助力公司成为体外诊断领域的引领者，指导公司战略布局，通过管理赋能和业务赋能不断向公司输送资源，以推动公司的高质量发展，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032818515987c0573a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>迪瑞医疗董秘回复：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n迪瑞医疗董秘回复：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-28 18:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032818515987c0573a&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，迪瑞医疗(300396)03月28日在投资者关系平台上答复投资者关心的问题。投资者：目前的控股股东，2025年就要到期了，未来是要转让股权吗？迪瑞医疗董秘：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任。控股股东一直坚定于助力公司成为体外诊断领域的引领者，指导公司战略布局，通过管理赋能和业务赋能不断向公司输送资源，以推动公司的高质量发展，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032818515987c0573a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999010052.SGD","symbol_name":"United Asia Pacific Real Estate Income Dis SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032818515987c0573a&s=b","article_id":"2422165007","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032818515987c0573a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422165007","pubTimestamp":1711623115,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"证券之星消息，迪瑞医疗03月28日在投资者关系平台上答复投资者关心的问题。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任。再次感谢您的关注与支持。以上内容由证券之星根据公开信息整理，由算法生成，与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999010052.SGD":"United Asia Pacific Real Estate Income Dis SGD","BK1583":"高瓴概念","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0414403682.SGD":"Blackrock Asia Pacific Equity Income A5 SGD-H","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2088748020.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","LU0738912210.USD":"Blackrock Asia Pacific Equity Income A6 USD","LU0594300419.USD":"富达中国消费基金A","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU2088748376.SGD":"Eastspring Investments - Asia Real Estate Multi Asset Income Cl ASDM SGD-H","BK1570":"华润系","SG9999009997.SGD":"United Asia Pacific Real Estate Income Acc SGD","BK1240":"房地产开发","LU0048597586.USD":"富达亚洲焦点A","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1521":"挪威政府全球养老基金持仓","BK1555":"内房股","01109":"华润置地","LU0173614495.USD":"富达中国焦点A","LU2088747998.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","09996":"沛嘉医疗-B","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","09997":"康基医疗","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU2088747725.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"A\" (USD) ACC","SG9999010078.USD":"UNITED ASIA PACIFIC REAL ESTATE INCOME (USDHDG) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0048580855.USD":"富达大中华区A","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU2088748293.HKD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"AHD\" (HKD) INC","BK1222":"医疗保健用品","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1589":"北水核心资产","BK1100":"医疗保健设备","IE0008368742.USD":"首域中国增长基金I Acc","BK1574":"生物医药B类股"},"translate_title":"Secretary of Dirui Medical replied: Thank you for your concern about the future development of the company. As the only medical device industry in the health sector of China Resources, we are deeply honored and shoulder heavy responsibilities","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1,"09997":1,"01109":0.9},"content_text":"证券之星消息，迪瑞医疗(300396)03月28日在投资者关系平台上答复投资者关心的问题。投资者：目前的控股股东，2025年就要到期了，未来是要转让股权吗？迪瑞医疗董秘：感谢您对公司未来发展的关注。作为华润大健康板块中唯一的医疗器械产业，我们深感荣幸并肩负重任。控股股东一直坚定于助力公司成为体外诊断领域的引领者，指导公司战略布局，通过管理赋能和业务赋能不断向公司输送资源，以推动公司的高质量发展，充分体现了控股股东对公司未来发展的坚定信心。再次感谢您的关注与支持。以上内容由证券之星根据公开信息整理，由算法生成，与本站立场无关。证券之星力求但不保证该信息（包括但不限于文字、视频、音频、数据及图表）全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422165007"}